\n
Stakeholder Engagement
Cross-Functional Team Leadership
Operational Excellence
What additional qualifications will make you a stronger candidate?
\nWhy Blueprint?
\nAt Blueprint Medicines, we achieve impactful results because of our global crew of compassionate innovators – the Blue Crew. Through authentic relationships and our collective entrepreneurial spirit and action, we are each empowered to take ownership and execute with strategic prioritization. We put trust in our people to break through norms and conventions using their individual strengths and insights, which drives our success.
\nThis is the place where the extraordinary becomes reality, and you could be part of it.
\nPatients are waiting. Are you ready to make the leap?
\nBlueprint Medicines is a fully integrated, commercial-stage, global biopharmaceutical company that invents life-changing medicines in two core, strategic areas of allergy/inflammation and oncology/hematology. We pursue discovery, development, and commercialization of therapies that potently and selectively target known drivers of disease, with focused investment in therapeutic areas where we can leverage our core expertise and business infrastructure to bring scale to our science. We are bringing an approved medicine to people living with systemic mastocytosis (SM) in the U.S. and Europe. Additionally, we have a pipeline of research and development programs that range from early science to advanced clinical trials in mast cell-mediated diseases, including SM and chronic urticaria, breast cancer, and other solid tumors vulnerable to CDK2 inhibition.
\n#LI-Remote
\n#LI-NJ1
","datePosted":"2025-03-13T07:15","employmentType":"FULL_TIME","jobLocation":[{"@type":"Place","address":{"@type":"PostalAddress","addressLocality":"Aachen, Germany","addressRegion":null,"addressCountry":"Germany"}},{"@type":"Place","address":{"@type":"PostalAddress","addressLocality":"Wenden, Germany","addressRegion":null,"addressCountry":"Germany"}}],"directApply":false,"hiringOrganization":{"@type":"Organization","name":"Blueprint Medicines","sameAs":"https://www.blueprintmedicines.com/","logo":"https://storage.googleapis.com/simplify-imgs/companies/924ee2a8-3a04-41ab-a6c1-a6ffa0d43de8/logo.png"},"identifier":{"@type":"PropertyValue","name":"Blueprint Medicines","value":"924ee2a8-3a04-41ab-a6c1-a6ffa0d43de8"}}Full-Time
No salary listed
Senior
Aachen, Germany + 1 more
More locations: Wenden, Germany
Field-based position in West Germany, specifically in the Köln/Bonn/Aachen area.
Upload your resume to see how it matches 8 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
Company Size
501-1,000
Company Stage
IPO
Headquarters
Cambridge, Massachusetts
Founded
2011
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Unlimited Paid Time Off
Commuter Benefits
Mental Health Support
Employee Stock Purchase Plan
Parental Leave
Proficio Capital Partners LLC makes new $1.01 million investment in Blueprint Medicines Co. (NASDAQ:BPMC).
Truist Financial Corp makes new investment in Blueprint Medicines Co. (NASDAQ:BPMC).
Blueprint Medicines highlights 'decade of leadership' in Mast Cell research with new AYVAKIT and BLU-808 data at AAAAI/WAO 2025.
-- Updated data show AYVAKIT® (avapritinib) was safe and effective for long-term treatment of ISM, with sustained symptom and quality-of-life benefit and no new safety signals with multiple years of therapy ---- AYVAKIT-treated patients achieved improvements in bone health based on an analysis of bone mineral density scans, underscoring the importance of treating patients early in the ISM disease course ---- BLU-808 healthy volunteer trial results demonstrate wide therapeutic window for modulating mast cell activity, affirming potential as best- and first-in-class oral wild-type KIT inhibitor --CAMBRIDGE, Mass., Feb. 28, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced data presentations reflecting its ongoing efforts to innovate the treatment of mast cell-driven diseases. The presentations include three-year median follow-up data from the registrational PIONEER trial demonstrating the strong long-term efficacy and safety of AYVAKIT® (avapritinib) in patients with indolent systemic mastocytosis (ISM), and real-world evidence further characterizing the substantial burden of the disease, highlighting the urgency to treat. In addition, the company will report positive data from the Phase 1 healthy volunteer trial evaluating BLU-808, an investigational, highly potent and selective oral inhibitor of wild-type KIT, consistent with top-line data previously announced in January 2025. A total of 14 data presentations, including two oral presentations, will be reported at the 2025 American Academy of Allergy, Asthma & Immunology (AAAAI) / World Allergy Organization (WAO) Joint Congress being held February 28-March 3 in San Diego."We are incredibly proud to showcase our mast cell therapy portfolio at AAAAI / WAO, with 14 presentations highlighting more than a decade of leadership and collaboration with the mast cell disease community, including renowned medical institutions pioneering innovative research and multi-disciplinary patient care," said Becker Hewes, M.D., Chief Medical Officer at Blueprint Medicines. "In ISM, new data have reinforced that AYVAKIT was very well-tolerated after multiple years of treatment, with a low discontinuation rate and safety results that have remained consistent with the safety profile from the placebo-controlled study as summarized in the FDA-approval label
Furthermore, Blueprint Medicines announced the appointment of Sherwin Sattarzadeh as Chief Business Officer, succeeding Helen Ho.